Globus Medical, Inc.
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Globus Medical, Inc. is a leading musculoskeletal solutions company specializing in the design, development, manufacturing, and commercialization of a broad portfolio of products for the spine, orthopedic trauma, and neuromodulation markets. Its core product offerings include spinal implants and biologics; orthopedic trauma fixation devices such as plates, nails, and screws; joint reconstruction products including hip and knee systems; enabling technologies like surgical navigation and robotics; and high-frequency neuromodulation devices for chronic pain management. The company operates extensively across the United States and has an expanding international presence, serving hospitals, ambulatory surgery centers, and healthcare providers. Founded in 2003, Globus Medical is headquartered in Audubon, Pennsylvania. Recent major developments include the strategic acquisition of Nevro Corporation in early 2025, which significantly broadened Globus Medical's neuromodulation portfolio with advanced high-frequency spinal cord stimulation technology, positioning the company to access a $2.5 billion market opportunity. The company also continues to expand its orthopedic trauma product line with several new FDA-cleared systems in 2024 and 2025, including the TENSOR Suture Button System, ANTHEM II Distal Radius Volar Plates, AUTOBAHN Trochanteric Nail PRO Instruments, and CAPTIVATE SOLA Headless Screws. Additionally, Globus Medical launched innovative anterior lumbar interbody fusion products such as the COHERE ALIF Spacer and Modulus ALIF Blades in 2025, enhancing its spine surgery portfolio. The company is undergoing integration of recent acquisitions including NuVasive to realize operational synergies while focusing on organic innovation, enhanced surgeon engagement, and scaling its hip and knee business. Globus Medical's industry segments encompass spinal surgery, orthopedic trauma, joint reconstruction, enabling surgical technologies, and neuromodulation. The company targets orthopedic surgeons, neurosurgeons, and healthcare institutions. Its growth strategy emphasizes organic product innovation combined with selective acquisitions and operational efficiency improvements under new leadership following a CEO transition in 2025. Globus Medical remains committed to advancing patient outcomes through superior engineering and a comprehensive range of musculoskeletal solutions.
Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform
Here's How GMED Is Capitalizing on the Musculoskeletal Market Boom
Does Globus Medical (GMED) Have the Potential to Rally 38.85% as Wall Street Analysts Expect?
GMED or PEN: Which Is the Better Value Stock Right Now?
Here's Why Globus Medical (GMED) is a Strong Value Stock
Here's How Financial Strength Remains a Key Advantage for GMED
Should You Buy, Hold or Sell GMED Stock Amid Musculoskeletal Boom?
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Globus Medical, Inc. (NYSE: GMED)
GMED's Robotics Leasing Shift Could Build Recurring Revenue
Reasons to Retain TransMedics Stock in Your Portfolio for Now
GMED Growth Drivers After NuVasive and What Q1 Signals
Looking for a Growth Stock? 3 Reasons Why Globus Medical (GMED) is a Solid Choice
Globus Medical (GMED) Upgraded to Strong Buy: Here's What You Should Know
3 Medical Instrument Stocks Exploring GenAI to Tackle Industry Woes
Globus Medical Inc (GMED) Shares Surge 5.1% -- What GF Score of 97 Tells Investors
GMED vs. SONVY: Which Stock Is the Better Value Option?
Why Globus Medical (GMED) is a Top Value Stock for the Long-Term
3 Highly Ranked Medical Stocks to Buy Now: DVA, GMED, PGNY
3 Reasons Why Growth Investors Shouldn't Overlook Globus Medical (GMED)
Down 13.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Globus Medical (GMED)